Patent · US Active

Histological markers for identifying non-small cell lung carcinoma patients for treatment with an anti-EGFR drug

US9921222B2 · kind B2 · utility

0Cited by

0References

2Claims

0Family size

Assignee

CROWN BIOSCIENCE, INC. (TAICANG) · CN

Inventors

Henry Qixiang Li · Russell, CA
Mengmeng YANG · Hefei, CN

Key dates

Filing date	Jul 31, 2013
Grant date	Mar 20, 2018
Priority date	—
Expiry date	Jul 31, 2033

Classification

Technology area (CPC G)Physics
CPC primaryG01N2800/52
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention provides methods for the treatment of lung cancer patients, especially NSCLC with SCC or PLC using a drug against EGFR, such as an anti-EGFR antibody treatment, e.g., cetuximab. In addition, the present invention provides methods for identification or selection of lung cancer patients for the treatment with a drug against EGFR, such as an anti-EGFR antibody treatment, e.g., cetuximab based on histological determinations.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.